ENTERA BIO LTD. Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019
ENTERA BIO LTD. (ENTX) had Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 of $5.49 per share as of 2020-12-31, per its 20-F filed 2021-03-18.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 · last filed 2021-03-18
- 2020-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $5.49.
- 2019-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $5.62.
- 2018-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $1.67.
- 2017-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $2.92.
| Period end | Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 |
|---|---|
| 2020-12-31 | $5.49 20-F · filed 2021-03-18 |
| 2019-12-31 | $5.62 20-F · filed 2021-03-18 |
| 2018-12-31 | $1.67 20-F · filed 2021-03-18 |
| 2017-12-31 | $2.92 20-F · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |